SYS-CON MEDIA Authors: Kevin Benedict, Gilad Parann-Nissany, Unitiv Blog, RealWire News Distribution, Jason Bloomberg

News Feed Item

Global Multiple Sclerosis (MS) Therapeutics Market Report

DUBLIN, April 11, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/btp9ds/global_multiple) has announced the addition of the "Global Multiple Sclerosis (MS) Therapeutics Market Report" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The analysts forecast the Global Multiple Sclerosis (MS) Therapeutics market to grow at a CAGR of 3.16 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rising diagnosis and treatment rates. The Global MS Therapeutics market has also been witnessing the emergence of biomarkers. However, the lack of therapies available to manage the progression of the disease could pose a challenge to the growth of this market. 

The report, the Global Multiple Sclerosis (MS) Therapeutics Market Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global MS Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Currently, there is an increase in the adoption of biomarkers that are 100 percent specific to RRMS conditions. The use of biomarkers proves to be a sensitive indicator of the slightest disease activity in MS patients. A highly specific protein biomarker for MS aids in quick and precise identification of patients with the disease, possibly before clinically relevant symptoms arise. Thus, the use of biomarkers helps prevent the significant neurodegeneration associated with the disease.

Recently, the Global MS market has witnessed various collaborations for MS biomarkers. Regulus Therapeutics and Biogen Idec entered into a collaboration to identify blood-based microRNAs as biomarkers for MS. It is believed by both partners that microRNA biomarkers aid in the selection of ideal patient segments in clinical trials and also in monitoring disease progression or relapse.

According to the report, one of the main drivers is the increase in the diagnosis and treatment of multiple sclerosis. This is because of the usage of the latest revised McDonald diagnostic criteria in the treatment of MS. The McDonald diagnostic criteria consist of a combination of clinical, imaging, and paraclinical tests used in the diagnosis of MS. This latest revision has helped in improving the detection of the symptoms of the disease. A McDonald diagnostic criterion helps improve the sensitivity from around 46 percent to 74 percent. This indirectly aids in diagnosing MS more rapidly than in the early days.

Further, the report states that one of the major challenges in the market is the lack of therapies for the management of the progressive form of the disease. The patients under this category take only symptomatic treatment to improve their quality of life.

Key Topics Covered: 

1. Executive Summary
2. List of Abbreviations
3. Introduction
4. Market Research Methodology
5. Scope of the Report
6. Market Landscape
7. Geographical Segmentation
8. Rate of Incidence and Prevalence
9. Vendor Landscape
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Other Reports in this Series

Companies Mentioned: 

  • AB Science
  • Abbvie Inc.
  • Active Biotech AB
  • Astra Zeneca plc
  • Bayer HealthCare AG
  • Biogen Idec Inc.
  • Glaxo Smith Kline plc
  • Glenmark Pharmaceuticals Ltd.
  • Hoffmann-La Roche Inc.
  • Merck Serono SA
  • Novartis AG
  • Sanofi SA.
  • Teva Pharmaceutical Industries Ltd.

For more information visit http://www.researchandmarkets.com/research/btp9ds/global_multiple


Media Contact: Laura Wood , +353-1-481-1716, [email protected]

SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.